Type

Range

Units

Status

Start Date

End Date

Financing

Study Design

Homepage

Brief description/objective

This study will evaluate the efficacy and safety of atezolizumab plus bevacizumab and chemotherapy compared with placebo plus bevacizumab and chemotherapy in patients with recurrent ovarian-, fallopian tube, or primary peritoneal cancer with 1st or 2nd relapse within 6 months after platinum-based chemotherapy or 3rd relapse.

Despite optimal primary surgery and carboplatin/paclitaxel
based chemotherapy the majority of patients with advanced ovarian cancer will relapse. Treatment options for recurrent disease depend on treatment free interval, prior therapy, BRCAstatus, symptoms and patient wish. Further treatment depends on eligibility for platinum-based treatment. Randomized trials have shown efficacy of platinum retreatment in 1st and 2nd relapse. In patients, who are not eligible for another platinum-based treatment a non-platinum-based drug like PLD, gemcitabine, paclitaxel, or topotecan is the cytotoxic treatment of choice. The AURELIA trial showed a significant PFS benefit of adding bevacizumab to monochemotherapy in this patient
cohort (HR 0.48; 95%CI 0.38-0.60; p<0.001) (4). Therefore, bevacizumab based treatment is a new standard option in patients with platinum-resistant ovarian cancer.